Magnetic Resonance imaging and spectroscopy in transgenic mice modeling alzheimer’s disease

In Vivo MR Techniques in Drug Discovery and Development

Volumn , Issue , 2006, Pages 95-110

  Mueggler, Thomas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249748786     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (105)

1. Selkoe, D. J., Alzheimer’s disease: genes, proteins, and therapy, Physiol. Rev., 81, 741, 2001.
2. Hampel, H. et al., Biological marker candidates of Alzheimer’s disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity, J. Neural. Transm., 111, 247, 2004.
3. Nestor, P. J., Scheltens, P., and Hodges, J. R., Advances in the early detection of Alzheimer’s disease, Nat. Rev. Neurosci., 5, S34, 2004.
4. Higgins, G. A. and Jacobsen, H., Transgenic mouse models of Alzheimer’s disease: phenotype and application, Behav. Pharmacol., 14, 419, 2003.
5. Phinney, A. L. et al., Mouse models of Alzheimer’s disease: the long and filamentous road, Neurol. Res., 25, 590, 2003.
6. Scorer, C. A., Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer’s disease, Drug Discovery Today, 6, 1207, 2001.
7. Nordberg, A., Towards an early diagnosis and treatment of Alzheimer’s disease, Int. Psychogeriatr., 15, 223, 2003.
8. Citron, M., Strategies for disease modification in Alzheimer’s disease, Nat. Rev. Neurosci., 5, 677, 2004.
9. Van Dam, D. et al., Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model, Psychopharmacology, 180, 177, 2005.
10. Alzheimer, A., Ueber eine eigenartige Erkrankung der Hirnrinde, Allg. Z. Psychiat. Psych.-Gericht. Med., 64, 146, 1907.
11. Graeber, M. B. et al., Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D, Neurogenetics, 1, 223, 1998.
12. Brion, J. et al., Mise en evidence immunologique de la protein tau au niveau des lesions de degenerescence neurofibrillaire de la maladie D’Alzheimer, Arch. Biol., 95, 229, 1985.
13. Selkoe, D. J., The molecular pathology of Alzheimer’s disease, Neuron, 6, 487, 1991.
14. Jarrett, J. T., Berger, E. P., and Lansbury, P. T. J., The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease, Biochemistry, 32, 4693, 1993.
15. Masliah, E. and Rockenstein, E., Genetically altered transgenic models of Alzheimer’s disease, J. Neural. Transm., 59, 175, 2000.
16. Hock, B. J. J. and Lamb, B. T., Transgenic mouse models of Alzheimer’s disease, Trends Genet., 17, S7, 2001.
17. German, D. C. and Eisch, A. J., Mouse models of Alzheimer’s disease: insight into treatment, Rev. Neurosci., 15, 353, 2004.
18. Games, D. et al., Alzheimer-type neuropathology in transgenic mice over-expressing V717F betaamyloid precursor protein, Nature, 373, 523, 1995.
19. Hsiao, K. et al., Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science, 274, 99, 1996.
20. Sturchler-Pierrat, C. et al., Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, Proc. Natl. Acad. Sci. USA, 94, 13287, 1997.
21. Chen, K. S. et al., Neurodegenerative Alzheimer-like pathology in PDAPP 717V-. F transgenic mice, Prog. Brain Res., 117, 327, 1998.
22. Staufenbiel, M. and Sommer, B., Transgenic animal models in the development of therapeutic strategies for Alzheimer’s Disease, In Molecular Biology of Alzheimer’s Disease: Genes and Mechanisms Involved in Amyloid Generation, Haass, C., Ed., Harwood Academic Publishers, Amsterdam, pp. 309-326, 1998.
23. Duff, K. et al., Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1, Nature, 383, 710, 1996.
24. Holcomb, L. et al., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat. Med., 4, 97, 1998.
25. Richards, J. G. et al., PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show agerelated cognitive deficits associated with discrete brain amyloid deposition and inflammation, J. Neurosci., 23, 8989, 2003.
26. Calhoun, M. E. et al., Neuron loss in APP transgenic mice, Nature, 395, 755, 1998.
27. Calhoun, M. E. et al., Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid, Proc. Natl. Acad. Sci. USA, 96, 14088, 1999.
28. Phinney, A. L. et al., Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice, J. Neurosci., 19, 8552, 1999.
29. Burgermeister, P. et al., Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models, Ann. N.Y. Acad. Sci., 903, 307, 2000.
30. Winkler, D. T. et al., Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy, J. Neurosci., 21, 1619, 2001.
31. Moechars, D. et al., Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain, J. Biol. Chem., 274, 6483, 1999.
32. Dodart, J. C. et al., Behavioral disturbances in transgenic mice overexpressing the V717F betaamyloid precursor protein, Behav. Neurosci., 113, 982, 1999.
33. Arendash, G. W. et al., Behavioral assessment of Alzheimer’s transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory, DNA Cell Biol., 20, 737, 2001.
34. Christie, R. et al., Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy, Am. J. Pathol., 158, 1065, 2001.
35. Kelly, P. H. et al., Progressive age-related impairment of cognitive behavior in APP23 transgenic mice, Neurobiol. Aging, 24, 365, 2003.
36. Van Dam, D. et al., Age-dependent cognitive decline in the APP23 model precedes amyloid deposition, Eur. J. Neurosci., 17, 388, 2003.
37. Chapman, P. F. et al., Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice, Nat. Neurosci., 2, 271, 1999.
38. Hsia, A. Y. et al., Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models, Proc. Natl. Acad. Sci. USA, 96, 3228, 1999.
39. Walsh, D. M. and Selkoe, D. J., Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration, Protein Pept. Lett., 11, 213, 2004.
40. Cummings, B. J. and Cotman, C. W., Image analysis of beta-amyloid load in Alzheimer’s disease and relation to dementia severity, Lancet, 346, 1524, 1995.
41. Morris, J. C. and Price, A. L., Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease, J. Mol. Neurosci., 17, 101, 2001.
42. Parvathy, S. et al., Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline, Arch. Neurol., 58, 2025, 2001.
43. Kuo, Y. M. et al., Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer’s disease brains, J. Biol. Chem., 276, 12991, 2001.
44. Gordon, M. N. et al., Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1_APP mouse, Exp. Neurol., 173, 183, 2002.
45. Brun, A., An overview of light and electron microscopic changes, In Alzheimer’s Disease: The Standard Reference Book, Reisberg, B., Ed., The Free Press, New York, pp. 37-47, 1983.
46. Wisniewski, H. M., Neuritic (senile) and amyloid plaques, In Alzheimer’s Disease: The Standard Reference Book, Reisberg, B., Ed., The Free Press, New York, pp. 57-61, 1983.
47. Huesgen, C. T. et al., In vitro MR microscopy of the hippocampus in Alzheimer’s disease, Neurology, 43, 145, 1993.
48. Grundke-Iqbal, I. et al., Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia, Acta Neuropathol, 81, 105, 1990.
49. Benveniste, H. et al., Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy, Proc. Natl. Acad. Sci. USA, 96, 14079, 1999.
50. 2 -weighted MR microscopic images, NMR Biomed., 15, 197, 2002.
51. Rudin, M. et al., Characterization of CNS disorders and evaluation of therapy using structural and functional MRI, Anal. Bioanal. Chem., 377, 973, 2003.
52. Lee, S. P. et al., Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer’s disease using MR microscopy without contrast reagents, Magn. Reson. Med., 52, 538, 2004.
53. Zhang, J. et al., Detection of amyloid plaques in mouse models of Alzheimer’s disease by magnetic resonance imaging, Magn. Reson. Med., 51, 452, 2004.
54. Vanhoutte, G. et al., In vivo MRI can discern amyloid plaques in the Alzheimer APP[V717I] mouse model, Proceedings of the International Society for Magnetic Resonance in Medicine, 10th Scientific Meeting Honolulu, 2002, p. 1205.
55. Jack, C. R. Jr et al., In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent, Magn. Reson. Med., 52, 1263, 2004.
56. Poduslo, J. F. et al., Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging, Neurobiol. Dis., 11, 315, 2002.
57. Wadghiri, Y. Z. et al., Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging, Magn. Reson. Med., 50, 293, 2003.
58. Nordberg, A., PET imaging of amyloid in Alzheimer’s disease, Lancet Neurol., 3, 519, 2004.
59. Klunk, W. E. et al., Imaging the pathology of Alzheimer’s disease: amyloid-imaging with positron emission tomography, Neuroimaging Clin. N. Am., 13, 781, 2003, ix.
60. Klunk, W. E. et al., Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B, Ann. Neurol., 55, 306, 2004.
61. Bacskai, B. J. et al., Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice, Proc. Natl. Acad. Sci. USA, 100, 12462, 2003.
62. Hintersteiner, M. et al., In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe, Nat. Biotechnol., 23, 577, 2005.
63. Sato, K. et al., Fluoro-substituted and 13C labeled styrylbenzene derivates for detecting brain amyloid plaques, Eur. J. Med. Chem., 39, 573-578, 2004.
64. Higuchi, M. et al., 19F and 1H MRI detection of amyloid b plaques in vivo, Nat. Neurosci., 8, 527, 2005.
65. Scheltens, P. et al., Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion, Lancet Neurol., 1, 13, 2002.
66. Knopman, D. S. et al., Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 56, 1143, 2001.
67. Frisoni, G. B. et al., Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC, J. Neurol. Neurosurg. Psychiat., 74, 1371, 2003.
68. Chetelat, G. and Baron, J. C., Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging, Neuroimage, 18, 525, 2003.
69. Petrella, J. R., Coleman, R. E., and Doraiswamy, P. M., Neuroimaging and early diagnosis of Alzheimer disease: a look to the future, Radiology, 226, 315, 2003.
70. De Leon, M. J. et al., MRI and CSF studies in the early diagnosis of Alzheimer’s disease, J. Intern. Med., 256, 205, 2004.
71. Kantarci, K. and Jack, C. R. Jr., Neuroimaging in Alzheimer disease: an evidence-based review, Neuroimaging Clin. N. Am., 13, 197, 2003.
72. Jack, C. R. Jr. et al., Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD, Neurology, 62, 591, 2004.
73. Mueggler, T., Functional Magnetic Resonance Imaging of the Murine Brain: Application to a Transgenic Model of Alzheimer’s Disease, Ph.D. thesis, University of Basel, 2002.
74. von Kienlin, M. et al., Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span, Neurobiol. Dis., 18, 32, 2005.
75. Redwine, J. M. et al., Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis, Proc. Natl. Acad. Sci. USA, 100, 1381, 2003.
76. Helpern, J. A. et al., MRI assessment of neuropathology in a transgenic mouse model of Alzheimer’s disease, Magn. Reson. Med., 51, 794, 2004.
77. Mueggler, T. et al., Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis, Eur. J. Neurosci., 20, 811, 2004.
78. Song, S. K. et al., Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition, Neurobiol. Dis., 15, 640, 2004.
79. Gilbert, J. J. and Vinters, H. V., Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage, Stroke, 14, 915, 1983.
80. Beckmann, N. et al., Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer’s disease, J. Neurosci., 23, 8453, 2003.
81. Krucker, T. et al., Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer’s disease, Neurol. Res., 26, 507, 2004.
82. Kantarci, K. et al., 1H MR spectroscopy in common dementias, Neurology, 63, 1393, 2004.
83. Dedeoglu, A. et al., Magnetic resonance spectroscopic analysis of Alzheimer’s disease mouse brain that express mutant human APP shows altered neurochemical profile, Brain Res., 1012, 60, 2004.
84. Block, W. et al., In-vivo proton MR-spectroscopy of the human brain: assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration, Amino Acids, 23, 317, 2002.
85. Small, S. A., Measuring correlates of brain metabolism with high-resolution MRI: a promising approach for diagnosing Alzheimer Disease and mapping its course, Alzheimer Dis. Assoc. Disord., 17, 154, 2003.
86. Belliveau, J. W. et al., Functional cerebral imaging by susceptibility-contrast NMR, Magn. Reson. Med., 14, 538, 1990.
87. Detre, J. A. et al., Perfusion imaging, Magn. Reson. Med., 23, 37, 1992.
88. Kwong, K. K. et al., Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation, Proc. Natl. Acad. Sci. USA, 89, 5675, 1992.
89. Williams, D. S. et al., Fast serial MRI of perfusion in the rat brain using spin inversion of arterial water, Bull. Magn. Reson., 15, 60, 1993.
90. Ogawa, S. et al., Brain magnetic resonance imaging with contrast dependent on blood oxygenation, Proc. Natl. Acad. Sci. USA, 87, 9868, 1990.
91. Buxton, R. B., Introduction to Functional Magnetic Resonance Imaging: Principles and Techniques, Cambridge University Press, Cambridge, 2002.
92. Nair, G. and Duong, T. Q., Echo-planar BOLD fMRI of mice on a narrow-bore 9.4 T magnet, Magn. Reson. Med., 52, 430, 2004.
93. Kuriwaki, J. et al., Comparison of brain activity between dopamine D2 receptor-knockout and wild mice in response to dopamine agonist and antagonist assessed by fMRI, Neurosignals, 13, 227, 2004.
94. Mueggler, T. et al., Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer’s disease, J. Neurosci., 23, 8231, 2003.
95. Mueggler, T. et al., Compromised hemodynamic response in amyloid precursor protein transgenic mice, J. Neurosci., 22, 7218, 2002.
96. Mueggler, T. et al., Bicuculline-induced brain activation in mice detected by functional magnetic resonance imaging, Magn. Reson. Med., 46, 292, 2001.
97. Ahrens, E. T. and Dubowitz, D. J., Peripheral somatosensory fMRI in mouse at 11.7 T, NMR Biomed., 14, 318, 2001.
98. Huang, W. et al., Magnetic resonance imaging (MRI) detection of the murine brain response to light: temporal differentiation and negative functional MRI changes, Proc. Natl. Acad. Sci. USA, 93, 6037, 1996.
99. Hyder, F. et al., Dynamic magnetic resonance imaging of the rat brain during forepaw stimulation, J. Cereb. Blood Flow Metab., 14, 649, 1994.
100. Mandeville, J. B. et al., Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation, Magn. Reson. Med., 39, 615, 1998.
101. Reese, T. et al., Cytoprotection does not preserve brain functionality in rats during the acute poststroke phase despite evidence of non-infarction provided by MRI, NMR Biomed., 13, 361, 2000.
102. Chen, Y. C. et al., Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data, Magn. Reson. Med., 38, 389, 1997.
103. Reese, T. et al., Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent, NMR Biomed., 13, 43, 2000.
104. Graham, G. D. et al., BOLD MRI monitoring of changes in cerebral perfusion induced by acetazolamide and hypercarbia in the rat, Magn. Reson. Med., 31, 557, 1994.
105. Sommer, B. et al., Transgenic approaches to model Alzheimer’s disease, Rev. Neurosci., 11, 47, 2000.